Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Anna Skwarska, Vinitha Mary Kuruvilla, Qi Zhang, Sovira Chaudhry, Naval Daver, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Deepa Sampath, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2023-187018

Published: 2023

Journal Articles

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

Margaux Poussard, Morgane Boichut, Imane Belakri, Sabeha Biichle, Maxime Fredon, Florian Renosi, Francine Garnache Ottou, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Fanny Delettre

Blood (2023) 142 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2023-185602

Published: 2023

Journal Articles

Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Richard B Lock, Kathryn Evans, Joanna Randall, Stephen W Erickson, Eric J Earley, Steven Neuhauser, Tim Stearns, Vivek Philip, Beverly A Teicher, Krystal Watkins, Callum M Sloss, Patrick A Zweidler-McKay, Malcolm A Smith

Blood (2022) 140 (Supplement 1): 8983–8984.

https://doi.org/10.1182/blood-2022-159867

Published: 2022

Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136791

Published: 2020

Journal Articles

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Claire Fritz, Scott M. Portwood, MS, MBA, Julie Adams, BS, Tara Cronin, BA, Linda Lutgen-Dunckley, Brandon L Martens, BS, Callum M. Sloss, PhD, Krystal Watkins, Yelena Kovtun, PhD, Sharlene Adams, PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 2647.

https://doi.org/10.1182/blood-2018-99-117214

Published: 2018

Journal Articles

IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo

Sharlene Adams, Meghan Kelly, Rebecca McCarthy, Alan Wilhelm, Krystal Watkins, Leanne Lanieri, Callum M. Sloss, Angela Romanelli

Blood (2017) 130 (Supplement 1): 1357.

https://doi.org/10.1182/blood.V130.Suppl_1.1357.1357

Published: 2017

Journal Articles

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Kathleen R Whiteman, MS, Paul Noordhuis, PhD, Russell Walker, MS, Krystal Watkins, MS, Yelena Kovtun, PhD, Lauren Harvey, BS, Alan Wilhelm, BS, Holly Johnson, BS, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD PhD, Robert J. Lutz, PhD

Blood (2014) 124 (21): 2321.

https://doi.org/10.1182/blood.V124.21.2321.2321

Published: 2014

Journal Articles

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Jutta Deckert, PhD, Jose F. Ponte, PhD, Jennifer A. Coccia, Leanne Lanieri, Sharon Chicklas, Yong Yi, Krystal Watkins, Rodrigo Ruiz-Soto, MD MSc, Angela Romanelli, PhD, Robert J. Lutz, PhD

Blood (2014) 124 (21): 3119.

https://doi.org/10.1182/blood.V124.21.3119.3119

Published: 2014

NARROW

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only